

Breast DCIS Prognostic Algorithmic Tests

- I. Breast DCIS prognostic algorithmic tests are considered **medically necessary** when:
 - A. The member has ductal carcinoma in situ (DCIS), **AND**
 - B. The tumor specimen contains at least 0.5 mm of DCIS, **AND**
 - C. The result of testing would aid in treatment decision-making (i.e., pursuing additional surgery or radiation therapy), **AND**
 - D. The member's DCIS was not removed via mastectomy (i.e., there is residual ipsilateral breast tissue).
- II. Breast DCIS prognostic algorithmic tests are considered **investigational** for all other indications.

REFERENCES

1. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Local Coverage Determination. MoIDX: Oncotype DX Breast Cancer for DCIS (Genomic Health) (L36912). Available at:
<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36912>